GlassScriptPhysician profile
Jason L Delcollo
NPI 1902033707
$3,700.25
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,279 · 2020: $1,381 · 2021: $40.02.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $486.00 | 2019-2020 | |
| Novo Nordisk INC | $405.55 | 2019-2020 | |
| Abbvie INC. | $284.05 | 2019-2021 | |
| Pfizer INC. | $282.77 | 2019-2020 | |
| Lilly USA, LLC | $247.16 | 2019-2020 | |
| Gilead Sciences, INC. | $240.28 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.18 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $213.57 | 2019-2020 | |
| Allergan, INC. | $196.13 | 2019-2020 | |
| Glaxosmithkline, LLC. | $171.10 | 2019-2020 | |
| Amarin Pharma, INC. | $133.89 | 2019-2020 | |
| Amgen INC. | $104.42 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $94.82 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $83.24 | 2019 | |
| Merck Sharp & Dohme LLC | $81.52 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $72.05 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $71.39 | 2019-2020 | |
| Daiichi Sankyo INC. | $39.09 | 2019 | |
| Horizon Therapeutics Plc | $37.69 | 2019 | |
| Genentech USA, INC. | $29.67 | 2019-2020 | |
| Orexo US, INC. | $21.63 | 2019 | |
| Antares Pharma, INC. | $19.95 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.77 | 2019 | |
| Eisai INC. | $19.61 | 2020 | |
| Philips North America LLC | $18.20 | 2020 | |
| Jazz Pharmaceuticals INC. | $17.84 | 2020 | |
| Indivior INC. | $17.77 | 2019 | |
| Hologic Sales and Service, LLC | $15.69 | 2020 | |
| Oxford Immunotec USA INC | $14.37 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.95 | 2019 | |
| Zyla Life Sciences, INC. | $12.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Delcollo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.